The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of the skin. It has more specific, targeted mechanisms and can be a suitable option for rapid itch relief and long-term use. The clinical trials showed improvement in clearance of skin condition and itch. The phosphodiesterase-4 (PDE4) inhibitor drug was previously approved for plaque psoriasis and seborrheic dermatitis for patients as topical foam.
As of June 2025, the drug is pending approval for use in pediatric patients at a younger age range.
Learn more:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf
Updated: June 2025
